财务数据和关键指标变化 - 第一季度销售额为58亿美元,核心收入下降4% [14] - 毛利率为60%,调整营业利润率为30.1%,下降170个基点 [14] - 调整后每股摊薄净收益为1.92美元,自由现金流14亿美元,自由现金流转换率超过130% [14] 各条业务线数据和关键指标变化 生物技术业务 - 核心收入下降17%,生物制药下降高个位数,发现和医疗下降约20% [16] - 生物制药订单环比第四季度增长中个位数,订单量对比率约为0.95 [17][41][42] - 北美和欧洲大客户正在逐步消化库存,预计第二季度末库存将基本正常化 [18] - 中国需求和活动水平持续疲弱,客户保持谨慎态度 [18] - 全年预计生物制药业务核心收入下降低个位数,第四季度实现高个位数或更高的增长 [19][20] 生命科学业务 - 核心收入下降3%,仪器业务整体下降中个位数 [23][24] - 发达市场制药和生物技术活动保持稳定,但需求水平较低 [23] - 学术和应用市场表现相对较好,特别是高端仪器 [24] - 中国受到去年刺激计划的高基数影响和需求下降拖累 [24] - 基因组学耗材业务实现低个位数增长 [24] - 长期来看,通过创新投资和战略收购,该业务处于有利位置 [25] 诊断业务 - 核心收入增长7.5% [26] - 临床诊断业务整体实现中个位数增长,贝克曼-柯尔特诊断连续5个季度中个位数增长 [26][27] - 利用达纳赫商业系统提升创新和商业执行能力,新产品推出提升了竞争力 [27] - 徕卡生物系统的Aperio GT450 DX数字病理扫描仪获得FDA 510(k)认证 [28][29] - 分子诊断业务赛默飞世尔增长两位数,继续获得市场份额 [30][31] - 赛默飞世尔呼吸系统业务收入约6.75亿美元,超出预期,全年预计约16亿美元 [30][31] - 赛默飞世尔安装基数超过55,000台,三倍于2019年,菜单采用和使用率持续提升 [31][32] 各个市场数据和关键指标变化 - 发达市场核心收入略有下降,诊断业务强劲增长抵消了生物技术的下降 [14] - 高增长市场下降低双位数,包括中国下降高个位数,经济环境仍然充满挑战 [14] 公司战略和发展方向及行业竞争 - 公司组合独特,业务处于有吸引力的终端市场,具有高毛利、高经常性收入的商业模式 [9][10][11] - 通过达纳赫商业系统持续改进,提升创新和执行能力,为客户提供突破性解决方案 [11][12][13] - 生物制药行业长期增长前景良好,生物制药批准数量大幅增加,为公司生物制药业务带来重大机遇 [20][21] - 生命科学工具业务通过创新投资和战略收购,处于有利位置,长期增长前景良好 [25] - 诊断业务通过新产品推出和商业执行力提升,竞争力不断增强 [27][28][29][32][33] 管理层对经营环境和未来前景的评论 - 第一季度表现超预期,订单和收入趋势改善支持全年指引 [9] - 生物制药订单环比改善,预计第二季度末库存将基本正常化 [17][18] - 生物制药行业长期增长前景良好,但短期内仍面临挑战 [19][20] - 生命科学工具业务短期内仍处于正常化过程,但长期前景向好 [23][24][25] - 诊断业务表现强劲,赛默飞世尔持续获得市场份额 [26][27][30][31][32][33] - 公司有信心实现全年指引,保持可持续长期表现 [9][35][36] 问答环节重要的提问和回答 问题1 **Jack Meehan提问** 生物制药业务订单环比改善的原因,以及客户类型和订单取消趋势 [40][41][42][46] **Rainer Blair和Matthew McGrew回答** - 第一季度订单环比增长中个位数,这是一个积极信号 [41][42] - 大型客户在北美和欧洲正在逐步恢复正常订单模式,库存正在逐步消化 [43] - 订单取消趋势有所改善,第一季度基本维持在0.95的水平 [46] - 总体来看,第一季度表现令人鼓舞,但公司维持全年指引不变 [45] 问题2 **Michael Ryskin提问** 第一季度毛利率和营业利润率超预期的原因,以及未来季度的趋势 [55][56][57][58][59] **Matthew McGrew回答** - 第二季度营业利润率约26%,主要是由于赛默飞世尔呼吸系统业务收入大幅下降 [56][57] - 公司业务存在一定的季节性,第一、四季度呼吸系统业务收入较高,第二、三季度较低 [58][59] - 这种季节性模式与疫情前有所不同,需要投资者关注 [58][59] 问题3 **Vijay Kumar提问** 中国市场和Abcam业务的情况 [81][82][83][84] **Rainer Blair回答** - 中国市场全年预计下降高个位数,公司正在密切关注相关政策刺激措施,但短期内不会产生重大影响 [81][82] - Abcam业务在中国的曝光很小,公司整体表现良好,增长中个位数,利润率超过30% [83] - 公司将继续推进Abcam的整合和达纳赫商业系统的实施,以发挥

财务表现 - Danaher（DHR）2024年第一季度营收为58亿美元，同比下降19.1%[1] - EPS为1.92美元，较去年同期的2.36美元有所下降[1] - 公司营收超出Zacks Consensus Estimate 2.85%，EPS也超出11.63%[2] - 诊断业务销售额为25.3亿美元，生命科学业务销售额为17.5亿美元，生物技术业务销售额为15.2亿美元[6] - 生命科学业务的营运利润为2.35亿美元，生物技术业务的营运利润为3.25亿美元[7][8] - 诊断业务的营运利润为8.3亿美元[9] 市场表现 - 在最新季度中，Danaher在多个受华尔街分析师广泛关注的指标上表现良好[5] - Danaher股票过去一个月的回报率为-4.7%，目前具有Zacks Rank 3（持有），预示着在短期内可能与整体市场表现一致[10]

财务表现 - Danaher (DHR)在本季度每股盈利为1.92美元，超过了Zacks Consensus Estimate的1.72美元，比去年同期的2.36美元有所下降[1] - 公司在过去四个季度中，四次超过了市场预期的每股盈利[2] - Danaher在2024年3月结束的季度实现了58亿美元的营收，超过了Zacks Consensus Estimate的2.85%，但相比去年同期的71.7亿美元有所下降[3] 股价走势 - 公司股价的短期走势将主要取决于管理层在财报电话会议上的评论[4]

Exhibit 99.1 Innovation at the speed of life Danaher Reports First Quarter 2024 Results WASHINGTON D.C., April 23, 2024 -- Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key First Quarter 2024 Results • Net earnings were $1.1 billion, or $1.45 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.92. • Revenues decreased ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Danaher (DHR) , which belongs to the Zacks Diversified Operations industry. When looking at the last two reports, this industrial and medical device maker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 10.19%, on average, in the last two quarters. For the last reported quarter, Danaher came out with earnings ...

Danaher Corporation (DHR) is scheduled to release first-quarter 2024 results on Apr 23, before market open. The company’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 6.8%. In the last reported quarter, its earnings of $2.09 per share beat the consensus estimate of $1.90 by 10%. Let’s see how things have shaped up for Danaher this earnings season. Key Factors and Estimates for Q1 Improving supply chains and strong price realization are exp ...

Wall Street analysts forecast that Danaher (DHR) will report quarterly earnings of $1.72 per share in its upcoming release, pointing to a year-over-year decline of 27.1%. It is anticipated that revenues will amount to $5.64 billion, exhibiting a decline of 21.3% compared to the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estima ...

公司业绩 - 公司市值为180.7亿美元，过去六个月股价上涨16.5%，行业增长为5.4%[2] - 公司目前持有Zacks Rank 2 (Buy)评级[2] - 公司受益于生命科学领域的实力，受到学术和生命科学研究市场的强劲需求推动[3] 产品创新 - 公司新产品如IDBS的Polar Insight和Molecular Devices的CellXpress.ai受到积极回应，有助于加快药物发现过程和更快地推出新疗法[4] 收购业务 - 公司专注于收购业务以获得新客户、地区和产品线，2023年12月收购了全球蛋白消耗品供应商Abcam plc，扩大了公司的生命科学部门[5] 公司战略 - 公司通过Danaher Business System (DBS)倡议，专注于产品创新、卓越产品质量、高效的员工建设和股东价值增值，促进公司增长[6] 股东回报 - 公司致力于通过股息支付回报股东，2023年支付的股息为8.21亿美元，同比增长0.4%，2024年2月季度股息率提高了12.5%至每股27美分[7]

Danaher (DHR) ended the recent trading session at $244.28, demonstrating a +0.98% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.11%. Meanwhile, the Dow experienced a rise of 0.8%, and the technology-dominated Nasdaq saw an increase of 1.24%. The industrial and medical device maker's shares have seen a decrease of 4.81% over the last month, not keeping up with the Conglomerates sector's loss of 4.23% and the S&P 500's gain of 0.48%. The investment community will ...

Danaher (DHR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this industrial and medical device maker have returned -3.4% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Diversified Operations industry, to which Danaher belongs, has lost 3.3% over this period. Now the key question is: Where could the stock be headed in t ...